Key result
Incretin-based therapies, including GLP-1 analogs and DPP-4 inhibitors, show potential to improve endothelial function, though current clinical data are conflicting and require large-scale trials.
Why the study?
Do incretin therapies (GLP-1 analogs and DPP-4 inhibitors) improve endothelial function?
Do incretin therapies (GLP-1 analogs and DPP-4 inhibitors) improve endothelial function?
This review explores the potential mechanisms and effects of incretin therapies on endothelial function, which may have implications for cardiovascular risk reduction in Type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Potential endothelial benefits of incretin therapies remain unproven; hypothesis-generating and should not yet change practice.
An impaired endothelial function has been recognized in the early stage of atherosclerosis, and is a major factor affecting the future development of cardiovascular events. Type 2 diabetes mellitus (T2DM) is widely prevalent, and is one of the most important risk factors for cardiovascular disease. T2DM is associated with increases in both morbidity and mortality, particularly from cardiovascular disease.New therapies based on the incretin hormone and its actions are now becoming widely used, and appear to offer advantages over conventional therapies by keeping the body weight steady and limiting hypoglycemia, while also achieving attractive glycemic control. However, there is little data available about the effects of incretins on the cardiovascular system.This review will focus on the effects of incretin therapies, including glucagon-like peptide-1 (GLP-1) analogs and dipeptidyl peptidase (DPP)-4 inhibitors, on the endothelial function, and will discuss the potential mechanisms underlying these effects.
No takes yet. Share an insight, caveat, or question.
Oyama et al. (2014) conducted a review in Type 2 diabetes mellitus and endothelial dysfunction. Incretin therapies (GLP-1 analogs and DPP-4 inhibitors) was evaluated. Incretin-based therapies, including GLP-1 analogs and DPP-4 inhibitors, show potential to improve endothelial function, though current clinical data are conflicting and require large-scale trials.
Synapse has enriched 10 related papers. Consider them for comparative context: